Second Vir-GSK monoclonal antibody to enter Phase 1/2 COVID-19 trials Vir Biotechnology and GSK will evaluate VIR-7832 in the early treatment of COVID-19 in a Phase 1b/2a trial starting in the first quarter of this year.
Preclinical data suggests VIR-7832, a neutralising COVID-19 antibody, has two distinguishing properties: an enhanced ability to clear infected cells and the potential to enhance virus-specific T cell function, which could help treat and/or prevent COVID-19 infection.
California’s Vir Biotechnology and GSK entered into a coronavirus collaboration in April 2020: using Vir’s proprietary monoclonal antibody platform tech to identify new and existing anti-viral antibodies for use against the COVID-19 pandemic. VIR-7832 is the second monoclonal antibody from the collaboration.
Sign of hope as infection rates across Liverpool City Region fall slightly liverpoolecho.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from liverpoolecho.co.uk Daily Mail and Mail on Sunday newspapers.
From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.